Poseida Therapeutics in $50 Million Investment Deal With Astellas
07 Août 2023 - 3:58PM
Dow Jones News
By Colin Kellaher
Poseida Therapeutics has signed a $50 million deal with Japan's
Astellas Pharma aimed at advancing the clinical-stage
biopharmaceutical company's cancer cell-therapy work.
San Diego-based Poseida on Monday said Astellas will invest $25
million for an 8.8% stake in the company, buying more than 8.33
million shares at $3 each, 84% above Friday's closing price of
$1.63.
Astellas will also pay $25 million for a right of exclusive
negotiation and first refusal to license Poseida's P-MUC1C-ALLO1
allogeneic CAR-T cell therapy in development for multiple solid
tumor indications.
Poseida said it is granting Astellas a board observer seat,
which includes the ability to attend scientific advisory board
meetings, and certain notice rights related to any potential change
of control.
Trading in Poseida shares was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 07, 2023 09:43 ET (13:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Poseida Therapeutics (NASDAQ:PSTX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Poseida Therapeutics (NASDAQ:PSTX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
